A brief review of donanemab (Kisunla®) for Alzheimer’s disease

In 2024, the US Food and Drug Administration approved another medication for the treatment of Alzheimer’s disease in its early stages. What is donanemab (Kisunla®)? Developed by Eli Lilly and Company, donanemab (Kisunla®) is a monoclonal antibody against amyloid beta. What is its FDA indication?  Donanemab has an FDA indication for “the treatment of Alzheimer’s…